Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Venous thrombosis during assisted reproduction: novel risk reduction strategies.

Nelson SM.

Thromb Res. 2013 Jan;131 Suppl 1:S1-3. doi: 10.1016/S0049-3848(13)00023-6.

PMID:
23452730
2.

New algorithm for OHSS prevention.

Papanikolaou EG, Humaidan P, Polyzos N, Kalantaridou S, Kol S, Benadiva C, Tournaye H, Tarlatzis B.

Reprod Biol Endocrinol. 2011 Nov 3;9:147. doi: 10.1186/1477-7827-9-147.

3.

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.

Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008046. doi: 10.1002/14651858.CD008046.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD008046.

PMID:
21069701
4.

Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.

Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R.

Reprod Biomed Online. 2006 Aug;13(2):198-201.

PMID:
16895632
5.

Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction.

La Marca A, D'Ippolito G.

Reprod Biomed Online. 2014 Feb;28(2):183-90. doi: 10.1016/j.rbmo.2013.10.012. Epub 2013 Oct 25. Review.

PMID:
24368127
6.

Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles.

Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I.

J Assist Reprod Genet. 2011 Dec;28(12):1197-203. doi: 10.1007/s10815-011-9627-4. Epub 2011 Sep 1.

7.

The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.

Majumder K, Gelbaya TA, Laing I, Nardo LG.

Eur J Obstet Gynecol Reprod Biol. 2010 Jun;150(2):166-70. doi: 10.1016/j.ejogrb.2010.02.029. Epub 2010 Mar 11.

PMID:
20223579
8.

Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.

Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, Schultze-Mosgau A.

Hum Reprod. 2007 May;22(5):1348-52. Epub 2007 Feb 15.

PMID:
17303632
9.

Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.

Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG.

Hum Reprod. 2005 Sep;20(9):2421-5. Epub 2005 May 12.

PMID:
15890731
10.

GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.

Griesinger G, Diedrich K, Devroey P, Kolibianakis EM.

Hum Reprod Update. 2006 Mar-Apr;12(2):159-68. Epub 2005 Oct 27. Review.

PMID:
16254001
11.

Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.

Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T.

Hum Reprod. 2006 May;21(5):1260-5. Epub 2006 Jan 26.

PMID:
16439507
12.

Ovarian stimulation in patients in risk of OHSS.

Soave I, Marci R.

Minerva Ginecol. 2014 Apr;66(2):165-78. Review.

PMID:
24848075
13.

Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.

D'Angelo A, Amso N.

Cochrane Database Syst Rev. 2002;(2):CD002806. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD002806.

PMID:
12076453
14.

Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos.

D'Angelo A.

Semin Reprod Med. 2010 Nov;28(6):513-8. doi: 10.1055/s-0030-1265679. Epub 2010 Nov 16. Review.

PMID:
21082511
15.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.

Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S.

Fertil Steril. 2011 May;95(6):2029-33, 2033.e1. doi: 10.1016/j.fertnstert.2011.01.163. Epub 2011 Mar 2.

PMID:
21371705
16.
17.

Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.

Manzanares MA, Gómez-Palomares JL, Ricciarelli E, Hernández ER.

Fertil Steril. 2010 Mar 1;93(4):1215-9. doi: 10.1016/j.fertnstert.2008.12.019. Epub 2009 Feb 6.

PMID:
19200978
18.

GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?

Kol S, Solt I.

J Assist Reprod Genet. 2008 Feb-Mar;25(2-3):63-6. doi: 10.1007/s10815-008-9198-1. Epub 2008 Feb 7. Review.

19.

Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.

Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R.

Hum Reprod. 2012 Mar;27(3):753-9. doi: 10.1093/humrep/der463. Epub 2012 Jan 16.

PMID:
22252086
20.

Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.

Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L.

Fertil Steril. 2012 Jun;97(6):1316-20. doi: 10.1016/j.fertnstert.2012.03.015. Epub 2012 Apr 3.

PMID:
22480822

Supplemental Content

Support Center